Liposome drug delivery systems

Claim 2

A liposome medicament delivery system comprising a medicament encapsulated in a liposome comprising an aliphatic lipid-sterol-water lamellae, wherein the aliphatic lipid is a sodium or potassium salt of a fatty acid having from 4 to 18 carbon atoms, in a lipid concentration which forms micelles above the critical micelle concentration, and wherein the sterol is present in an amount capable of being penetrated by the micelles of the aliphatic lipid.

Claim 3

The liposome medicament delivery system according to claim 1 wherein the sodium or potassium salt of the fatty acid has from 14 to 18 carbon atoms.

Claim 4

The liposome medicament delivery system according to claim 2 wherein the fatty acid salt is sodium oleate or potassium oleate.

Claim 5

The liposome delivery system according to claim 1 wherein the sterol is cholesterol.

Claim 6

The liposome medicament delivery system according to claim 4 wherein the sodium or potassium salt of the fatty acid has from about 14 to 18 carbon atoms.

Claim 7

The liposome medicament delivery system according to claim 5 wherein the fatty acid salt is sodium or potassium oleate.

Claim 8

The liposome medicament delivery system according to claim 1 wherein the weight percent composition of the liposome is from about 0.03% to about 20% aliphatic lipid, from about 1.0% to about 55% sterol, and from about 45% to about 97% water.

Claim 9

The liposome medicament delivery system according to claim 7 wherein the weight percent composition of the liposome composition is from about 1.0% to about 15% aliphatic lipid, from about 1.0% to about 40% sterol, and from about 50% to about 97% water.

Claim 10

The liposome medicament delivery system according to claim 8 wherein the weight percent composition of the liposome is from about 5.0% to about 10% aliphatic lipid, from about 1.0% to about 10% sterol and from about 75% to about 97% water.

Claim 11

The liposome medicament delivery system according to claim 4 wherein the weight percent composition of the liposome is from about 0.03% to about 20% fatty acid salt, from about 1.0% to about 55% cholesterol, and from about 45% to about 97% water.

Claim 12

The liposome medicament delivery system according to claim 10 wherein the weight percent composition of the liposome is from about 1.0% to about 15% fatty acid salt, from about 1.0% to about 40% cholesterol, and from about 50% to about 97% water.

Claim 13

The liposome medicament delivery system according to claim 11 wherein the weight percent composition of the liposome is from about 5.0% to about 10% fatty acid salt, from about 1.0% to about 10% cholesterol and from about 75% to about 97% water.

Claim 14

A process for the preparation of a liposome medicament delivery system according to claim 1 which comprises subjecting a sterol to an aqueous micellar solution of an aliphatic lipid and a medicament for a time sufficient for the micelles to penetrate the sterol and subsequently reducing the particle size of the resultant liquid crystals to form the liposome.

Claim 15

A process for the preparation of a liposome medicament delivery system according to claim 1 which comprises adding a sterol to an aqueous medicament-aliphatic lipid mixture dissolved in a solvent, reducing the resultant liquid crystals to liposomes and evaporating the solvent to recover the liposomes.

Claim 16

A process for the preparation of a liposome medicament delivery system according to claim 1 which comprises dissolving a sterol and a medicament in a mutual solvent, evaporating the solvent, contacting the resultant sterol-medicament mixture with an aqueous micellar solution of an aliphatic lipid for a time sufficient for the micells and medicament to penetrate the sterol, and subsequently reducing the particle size of the resultant liquid crystals to form the liposome.

Claim 17

The process according to claim 13 wherein the pH of the liposome system is adjusted by contacting the liposome system with a pharmaceutically acceptable mineral acid, organic acid or buffer solution.

Claim 18

The process according to claim 16 wherein the pH adjustment is affected prior to particle size reduction of the liquid crystals.

Claim 19

The process according to claim 14 wherein the pH of the liposome system is adjusted by contacting the liposome system with a pharmaceutically acceptable mineral acid, organic acid or buffer solution.

Claim 20

The process according to claim 18 wherein the pH adjustment is affected prior to particle size reduction of the liquid crystals.

Claim 21

The process according to claim 15 wherein the pH of the liposome system is adjusted by contacting the liposome system with a pharmaceutically acceptable mineral acid, organic acid or buffer solution.

Claim 22

The process according to claim 20 wherein the pH adjustment is affected prior to particle size reduction of the liquid crystals.